Role of positron emission tomography in the management of breast cancer

Breast

Volumn 8, Issue 6, 1999, Pages 303-310

  Smith, I C ^a   Gilbert, F J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ANTINEOPLASTIC AGENT; CARBON 11; FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; LEUCINE; METHIONINE C 11; OXYGEN 15; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; THYMIDINE; TRYPTOPHAN; VALINE; WATER O 15;

BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COST; DIAGNOSTIC ACCURACY; DRUG MONITORING; DRUG RESPONSE; FEMALE; GLYCOLYSIS; HUMAN; LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCINTILLATION CAMERA;

EID: 0033302422     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.1999.0086     Document Type: Article

References (37)

1. Overview of the current status of PET in breast cancer imaging
2. Gamma emission imaging in the management of breast disorders
3. Positron ranges obtained from biomedically important positron-emitting radionuclides
4. Enzyology of cancer cells (Second of two parts)
5. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues
6. Quantitating tumour glucose metabolism with FDG and PET
7. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benifit oncology?
8. 18F]Fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice
9. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease
10. Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays
11. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
12. Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose
13. Evaluation of preoperative chemotherapy using PET with flourine-18-fluorodeoxyglucose in breast cancer
14. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
15. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?
16. PET imaging of breast cancer with fluorine-18-radiolabeled estrogens and progestins
17. PET assessement of subclinical hormone flare reactions as a predictor of hormone response in advanced ER+ve breast cancer
18. [F-18]-Fluoroestradiol (FES) and positron emission tomography to measure estrogen receptor expression in breast cancer
19. 11C] Tyrosine PET
20. Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-D-glucose (FDG) PET
21. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
22. 18F]Fluoro-2-Deoxy-D-Glucose
23. New equipment in nuclear medicine dual-headed FDG coincidence detection cameras
24. Carbon-11 labelled tyrosine to study tumour metabolism by positron emission tomography (PET)
25. 18]Fluorodeoxyglucose and positron emission tomography
26. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with radiolabled glucose analogue 2-(18F)-fluoro-2-deoxy-D-glucose
27. Positron emission tomography of glucose metabolism in breast cancer. Potential for tumor detection, staging, and evaluation of chemotherapy
28. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
29. Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers
30. 18-F-FDG be considered as the best method?
31. 18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
32. Diagnostic value of positron emission tomography for detecting breast cancer
33. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer
34. Assessement of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabelled 2-(Flourine-18)-fluoro-2-deoxy-D-glucose
35. Prospective evaluation of fluorine-18 flurodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunohistochemistry
36. 18F-Fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: The experience of the national cancer institute of Milan
37. Staging the axilla in breast cancer: Accurate invivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose